Order Matters: The Art and Science of Myeloma Drug Sequencing

Examining the who, what, when, where, and why of myeloma treatment In 1844, Thomas Alexander Bean, one of the first documented patients with multiple myeloma (MM), underwent a battery of treatments – blood-letting, cupping, and...

Online Exclusives

Proposed Budget Would Cut Cancer and Biomedical Research Funding

The Trump administration’s proposed budget for 2018 includes nearly $6 billion in budget cuts to the National Institutes of Health (NIH) – an approximate...

MSC-100-IV Receives Fast-Track Designation

The U.S. Food and Drug Administration has granted fast-track designation for MSC-100-IV for pediatric patients with steroid-refractory acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic...

News

From the Blood Journals

Can Pomalidomide Plus Dexamethasone “Rescue” Patients With Relapsed/ Refractory Amyloid Light-Chain...

Patients with amyloid light-chain (AL) amyloidosis are often treated upfront with combinations of alkylating agents and bortezomib; when they don’t respond to this regimen...

Encouraging Trends in Six-Month Mortality in Amyloid Light-Chain Amyloidosis

With recent advances in diagnosis, treatment, and response assessment, clinicians have observed a significant decrease in six-month mortality (p<0.001) among patients with amyloid light-chain...

Latest Videos

video

Stephen M. Ansell, MD, PhD: Nivolumab Moves to Hematology

Dr. Ansell, a speaker in the Special Education Session on Newly Approved Drugs, discusses the growing role of nivolumab in hematologic malignancies.
video

Eugenia Vicky Asare, MD: Multidisciplinary Care Saves Lives Among Pregnant Women...

Dr. Asare shares how instituting simple protocols and a multidisciplinary approach dramatically reduced the mortality rate of pregnant women with sickle cell disease living...
video

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

Mark J. Levis, MD, PhD, discusses the results of a phase I/II trial of ASP2215, which was shown to potently, selectively, and sustainably inhibit...
video

Ruxolitinib in CMML: Study Shows Promising Results

Eric Padron, MD, shares results from the phase I study of ruxolitinib in chronic myelomonocytic leukemia, a rare type of myelodysplastic, myeloproliferative neoplasm with...

On Location

A Tale of Two Proteasome Inhibitors: Carfilzomib Versus Bortezomib in Multiple Myeloma

At the 16th International Myeloma Workshop (IMW), two clinical trials of patients with newly diagnosed...

Denosumab Delays Skeletal-Related Events in Newly Diagnosed Multiple Myeloma

Denosumab (a monoclonal antibody that targets the RANK ligand) was noninferior to zoledronic acid (ZA)...

The Multiple Myeloma Genome Project: Developing a Risk Stratification System for Multiple Myeloma

An update from the Multiple Myeloma Genome Project (MMGP), presented at the 16th International Myeloma...

Early Studies Reveal Efficacy, Safety Concerns With Vadastuximab Talirine in Patients With Acute Myeloid Leukemia

Early studies of vadastuximab talirine (33A) in patients with acute myeloid leukemia (AML) have shown...

Phase I Study Shows Venetoclax Active in Patients With Relapsed/Refractory Myeloma

The B-cell lymphoma/leukemia-2 (BCL-2) inhibitor venetoclax may be a new option for patients with heavily...

Newly Approved Drugs: How to Use Them in Practice

In 2016, the U.S. Food and Drug Administration (FDA) approved several new therapies for the...

Latest Headlines

Advertisement

ASH Directions

The ASH Bridge Grant Program, Announcing the 2017 TRTH Program Participants, and more

Thursday, July 21st, 2016
Apply for the ASH Bridge Grant Program ASH is accepting applications for the Bridge Grant Program through May 1, 2017. The program was created to...

March 2017: ASH Joins Medical Groups in Expressing Concern Over Immigration Executive Order, and...

Thursday, July 21st, 2016
ASH Joins Medical Groups in Expressing Concern Over Immigration Executive Order President Donald Trump’s executive order of January 27, which suspended “issuance of visas and...

Sign up for our e-Newsletter!

Fred Hutch Launches APOLLO Network for the Cancer Moonshot Initiative, Univeristy of Arizona to...

Thursday, July 21st, 2016
Fred Hutchinson Researchers to Assess Protein Assays for the Cancer Moonshot Initiative As part of the Cancer Moonshot initiative, the APOLLO (Applied Proteogenomics Organizational Learning...

Richard Pazdur Named Director of Oncology Center of Excellence, Be The Match Foundation® Receives...

Thursday, July 21st, 2016
Stephen Gottschalk Joins St. Jude Children’s Research Hospital Stephen Gottschalk, MD, was named chair of the Department of Bone Marrow Transplantation and Cellular Therapy at...

Remembering Peter C. Nowell, MD, Niels Borregaard, MD, PhD, Laurence Boxer, MD, and more

Thursday, July 21st, 2016
Peter C. Nowell, MD (1928-2016) Peter C. Nowell, MD, an acclaimed researcher and co-discoverer of the Philadelphia chromosome, which pointed for the first time to...

Order Matters: The Art and Science of Myeloma Drug Sequencing

Thursday, July 21st, 2016
Examining the who, what, when, where, and why of myeloma treatment In 1844, Thomas Alexander Bean, one of the first documented patients with multiple myeloma...

Diversity Evolution

Thursday, July 21st, 2016
The United States is becoming more diverse. Is the medical education system adapting quickly enough? The need for increased diversity in the medical profession is...

Affordable Care Act: Exit, Stage Right

Thursday, July 21st, 2016
The rollback of the Affordable Care Act (ACA) is underway. Within hours of taking the oath of office on January 20, President Donald Trump...